Dr. Charlie Strange is a Professor of Pulmonary and Critical Care Medicine at MUSC with faculty appointments in the Department of Medicine and the Department of Graduate Studies. His clinical interests include chronic obstructive pulmonary disease (with specialty interest in alpha-1 antitrypsin deficiency and bronchoscopic lung volume reduction) and interstitial lung disease (with specialty interest in the connective tissue diseases).
Dr. Strange is the Principal Investigator for the NIH Rare Lung Disease Consortium at MUSC that will study CT lung densitometry in alpha-1 antitrypsin deficiency, the efficacy and safety of rapamycin in lymphangioleiomyomatosis (LAM), and macrophage functioning in alveolar proteinosis. This NIH program seeks to establish centers of excellence that can be extended to study other rare diseases.
Dr. Strange also is the Principal Investigator for the Alpha-1 Foundation Research Registry, the largest registry of individuals with alpha-1 antitrypsin deficiency or the carrier state in the world. The Registry is used to support research on new therapies, genetic linkage studies, and social sciences research. The Alpha Coded Testing (ACT) study provides confidential testing for alpha-1 antitrypsin deficiency.
Connective tissue disease studies in collaboration with the Division of Rheumatology include the Scleroderma Lung Study, a prospective evaluation of cyclophosphamide vs. placebo for scleroderma interstitial lung disease. Dr. Strange is an active investigator in the MUSC pulmonary hypertension center and its associated clinical trials.
Dr. Strange is available for physician consultations on the above research studies and continues active inpatient and outpatient clinical service. For this activity and teaching he has been listed in “Best Doctors in America” 2003-2006 for General Pulmonary and Critical Care Medicine, Interstitial Lung Diseases, and Chronic Obstructive Pulmonary Disease. In 2006 he was a MUSC Medical Student Faculty Excellence Award nominee.